{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:37:59Z","timestamp":1794584279482,"version":"4.9.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Public Health Service"},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hatch and Animal Health Funds"},{"name":"Egyptian Government Scholarship"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.vaccine.2018.09.031","type":"journal-article","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T18:21:09Z","timestamp":1537899669000},"page":"6744-6751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy"],"prefix":"10.1016","volume":"36","author":[{"given":"Ekramy E.","family":"Sayedahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed O.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulma I.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A.","family":"York","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaprakash","family":"Gangappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suryaprakash","family":"Sambhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh K.","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.09.031_b0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41417-017-0002-1","article-title":"Development of an adenovirus vector vaccine platform for targeting dendritic cells","volume":"25","author":"Sharma","year":"2018","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.vaccine.2018.09.031_b0010","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1080\/21645515.2016.1165908","article-title":"Adenoviral vector-based strategies against infectious disease and cancer","volume":"12","author":"Zhang","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.09.031_b0015","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.vaccine.2018.09.031_b0020","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1517\/14712598.2010.519332","article-title":"Production of adenovirus vectors and their use as a delivery system for influenza vaccines","volume":"10","author":"Vemula","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2018.09.031_b0025","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.vaccine.2005.08.101","article-title":"Development of nonhuman adenoviruses as vaccine vectors","volume":"24","author":"Bangari","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.031_b0030","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1128\/JVI.02192-06","article-title":"Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways","volume":"81","author":"Zhu","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.09.031_b0035","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/gt.2010.1","article-title":"Evaluation of cross-reactive cell-mediated immune responses among human,bovine and porcine adenoviruses","volume":"17","author":"Sharma","year":"2010","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2018.09.031_b0040","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1128\/JVI.80.4.1959-1964.2006","article-title":"Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization","volume":"80","author":"Gao","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.09.031_b0045","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(06)68076-8","article-title":"Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice","volume":"367","author":"Hoelscher","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.09.031_b0050","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/sj.clpt.6100418","article-title":"New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice","volume":"82","author":"Hoelscher","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.vaccine.2018.09.031_b0055","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.vaccine.2004.07.043","article-title":"Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans","volume":"23","author":"Van Kampen","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.031_b0060","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S1473-3099(12)70345-6","article-title":"Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study","volume":"13","author":"Gurwith","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.031_b0065","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S1473-3099(15)00266-2","article-title":"High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial","volume":"15","author":"Liebowitz","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.031_b0070","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121077","article-title":"Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial","volume":"3","author":"Kim","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.vaccine.2018.09.031_b0075","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1086\/529522","article-title":"A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses","volume":"197","author":"Hoelscher","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.031_b0080","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.virusres.2004.05.003","article-title":"Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture","volume":"105","author":"Bangari","year":"2004","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2018.09.031_b0085","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/00002030-200405210-00019","article-title":"Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector","volume":"18","author":"Kostense","year":"2004","journal-title":"Aids"},{"key":"10.1016\/j.vaccine.2018.09.031_b0090","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1128\/CDLI.11.2.351-357.2004","article-title":"Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States","volume":"11","author":"Nwanegbo","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2018.09.031_b0095","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/JCM.01249-06","article-title":"Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa","volume":"44","author":"Thorner","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2018.09.031_b0100","doi-asserted-by":"crossref","first-page":"e33428","DOI":"10.1371\/journal.pone.0033428","article-title":"Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine","volume":"7","author":"Pandey","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.09.031_b0105","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0264-410X(94)00028-L","article-title":"Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species","volume":"13","author":"Taylor","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.031_b0110","doi-asserted-by":"crossref","first-page":"11349","DOI":"10.1073\/pnas.93.21.11349","article-title":"Applications of pox virus vectors to vaccination: an update","volume":"93","author":"Paoletti","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2018.09.031_b0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","article-title":"Characteristics of a human cell line transformed by DNA from human adenovirus type 5","volume":"36","author":"Graham","year":"1977","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2018.09.031_b0120","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.1128\/JVI.76.12.5882-5892.2002","article-title":"Development and characterization of bovine x human hybrid cell lines that efficiently support the replication of both wild-type bovine and human adenoviruses and those with E1 deleted","volume":"76","author":"van Olphen","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.09.031_b0125","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.cgt.7700761","article-title":"Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1","volume":"11","author":"Noblitt","year":"2004","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.vaccine.2018.09.031_b0130","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/viro.1995.1553","article-title":"Pathogenesis and immunogenicity of bovine adenovirus type 3 in cotton rats (Sigmodon hispidus)","volume":"213","author":"Mittal","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.09.031_b0135","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0264-410X(00)00170-5","article-title":"Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response","volume":"19","author":"Mittal","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.031_b0140","first-page":"1145","article-title":"Correlation between adenovirus-neutralizing antibody titer and adenovirus vector-mediated transduction efficiency following intratumoral injection","volume":"32","author":"Tomita","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.vaccine.2018.09.031_b0145","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/mt.2008.12","article-title":"Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus","volume":"16","author":"Singh","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2018.09.031_b0150","doi-asserted-by":"crossref","first-page":"e62496","DOI":"10.1371\/journal.pone.0062496","article-title":"Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness","volume":"8","author":"Vemula","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.09.031_b0155","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3201\/eid1201.051237","article-title":"Cell-mediated protection in influenza infection","volume":"12","author":"Thomas","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.031_b0160","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1006\/cimm.2001.1835","article-title":"Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function","volume":"211","author":"Sambhara","year":"2001","journal-title":"Cell Immunol"},{"key":"10.1016\/j.vaccine.2018.09.031_b0165","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1128\/JVI.01615-07","article-title":"Induction of heterosubtypic immunity to influenza virus by intranasal immunization","volume":"82","author":"Quan","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.09.031_b0170","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.031_b0175","series-title":"19 - Xenogenic adenoviral vectors A2 \u2013 Curiel, David T. Adenoviral vectors for gene therapy","first-page":"495","author":"Mittal","year":"2016"},{"key":"10.1016\/j.vaccine.2018.09.031_b0180","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1006\/viro.2000.0350","article-title":"Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy","volume":"272","author":"Moffatt","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.09.031_b0185","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2013.228","article-title":"Circumventing antivector immunity: potential use of nonhuman adenoviral vectors","volume":"25","author":"Lopez-Gordo","year":"2014","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2018.09.031_b0190","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13\u201319)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.09.031_b0195","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1016\/j.vaccine.2018.06.024","article-title":"Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses","volume":"36","author":"Vujadinovic","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.031_b0200","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1086\/509258","article-title":"Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector","volume":"194","author":"Catanzaro","year":"2006","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1831291X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1831291X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T01:49:32Z","timestamp":1605059372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1831291X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":40,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0264410X1831291X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.09.031","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.09.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}